PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It has already been proved useful when implemented late after cardiac arrest, and its immediate use could be more beneficial. Adverse effects such as cardiac arrhythmia, infection and coagulopathy lead to abandon protocols with moderate hypothermia (28-32 C°).

Low hypothermia (32-34 C°) post cardiorespiratory arrest is recommended but classical approaches make it difficult to maintain a stable temperature, therefore a device with automatic feedback could be useful.

The study randomized 36 patients post cardiorespiratory arrest (26 shockable rhythm, 10 asystole) to be cooled to 32°C vs.34°C by intravenous infusion of saline followed by a catheter Icy 9.3F implantation (ZOLL Medical Corporation, Chelmsford, MA) in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). 

Temperature was maintained for 24 hrs followed by 12 to 24 hrs of rewarming. Primary end point was survival free from severe dependence (Barthel index score ≥ 60) at 6 months. 44.4% of the 32 C° group reached primary end point vs. 11.1% of 34 C° group (p=0.12). All patients with asystole died within follow up. But from patients with initial shockable rhythm 61% of those assigned to 32°C were alive and free from severe dependence at six months, compared to 15.4% of those assigned to 34°C (p=0,0002). Complications incidence was similar in both groups.

Conclusion: this trial suggests that a cooling target of 32 C° in out of hospital cardiorespiratory arrest survivors could be beneficial.

Comment: though several questions remain unanswered, this therapy appears premising for this small group of patients. More definite results require further and larger trials

6_esteban_lopez_desa
Esteban Lopez-de-Sa
2012-11-06

Original title: Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Hospital Cardiac Arrest.

More articles by this author

SWISS AMI: Stem cells infusion after primary angioplasty

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or...

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with...

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due...

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....